EGFR-Non-Small Cell Lung Cancer – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033
Patients with Non-small cell lung cancer (NSCLC) harboring an epidermal growth factor receptor (EGFR) mutation constitute a distinct cohort. Their cancer's etiology, clinicopathological characteristics, prognosis, and treatment approaches diverge from other NSCLC patients. EGFR mutations manifest in approximately 40%–60% of Southeast Asian individuals or 10%–20% of Caucasians diagnosed with lung adenocarcinomas. While prevalent among non-smokers or light smokers, EGFR mutation-positive tumors may also occur in other smoking profiles. Notably, the rise in non-smoking habits has led to a higher proportion of female patients exhibiting EGFR mutations compared to males. In the Iressa Pan Asian Survival Study (IPASS) trial, which enrolled Asian non-smokers or non-smokers with lung adenocarcinoma, females constituted 80% of the participant pool.
Thelansis’s
“EGFR-Non-Small Cell Lung Cancer Market Outlook, Epidemiology, Competitive
Landscape, and Market Forecast Report – 2023 To 2033" covers disease
overview, epidemiology, drug utilization, prescription share analysis,
competitive landscape, clinical practice, regulatory landscape, patient share,
market uptake, market forecast, and key market insights under the potential EGFR-Non-Small
Cell Lung Cancer treatment modalities options for eight major markets (USA,
Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights of EGFR-Non-Small Cell
Lung Cancer across 8 MM market from the centre of Excellence/ Public/ Private
hospitals participated in the study. Insights around current treatment
landscape, epidemiology, clinical characteristics, future treatment paradigm,
and Unmet needs.
EGFR-Non-Small
Cell Lung Cancer Market Forecast Patient Based Forecast Model (MS.
Excel Based Automated Dashboard), which Data Inputs with sourcing, Market
Event, and Product Event, Country specific Forecast Model, Market uptake and
patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and
pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice
has been established based on a deep understanding of the pharma/biotech
business environment to provide an optimized support system to all levels of
the decision-making process. It enables business leaders in forward-thinking
and proactive decision-making. Thelansis supports scientific and commercial
teams in seamless CI support by creating an AI/ ML-based technology-driven
platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment